S&P 500 7,568.92 +0.36%
Nasdaq 25,372.01 +0.83%
S&P/TSX 35,532.28 −0.75%
Apple 331.90 −1.90%
Nvidia 206.69 +2.29%
Microsoft 520.99 +2.74%
Shopify 200.19 −8.02%
Royal Bank 285.42 −0.28%
CAD/USD 0.7169 +0.24%
PRE-MKT · 05:20 ET
Market ClerkRecap
Wed Nov 4 · pre-market3 signals on Nov 3175 insider buys this week · $365.2MCIRO short report next: Nov 15The week ahead

LIMNW

Liminatus Pharma, Inc.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
No price history available

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Who holds it

SEC 13F · LATEST QUARTER PER FUND
None of the 15 tracked funds disclose LIMNW in their latest 13F. The funds we follow.

13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.

Stakes of 5% or more

SCHEDULE 13D / 13G · LATEST PER HOLDER · TWO YEARS
No 13D or 13G filing on LIMNW in the last two years from the filings we read (13G only for companies we track; the sweep began Sep 2026).

A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.

Watch LIMNW. Know when insiders buy.
One email the day a filing lands. Free.